Table 1 Clinical parameters in low IGF-1 and standard IGF-1 groups.

From: Insulin-like growth factor-1 levels are associated with high comorbidity of metabolic disorders in obese subjects; a Japanese single-center, retrospective-study

 

Low IGF-1 group (n = 17)

Standard IGF-1 group (n = 47)

P value

All subjects (n = 64)

Sex (male/female)

5/12

21/26

0.39

26/38

Age (years)

39.0 [30.0, 43.0]

40.0 [33.5, 55.0]

0.39

39.0 [32.8, 52.0]

IGF-1 (ng/mL)

72.0 [47.0, 91.0]

134.0 [118.0, 156.5]

 < 0.001

124.0 [91.0, 143.0]

IGF-1 SDS

 − 2.7 [− 3.4, − 2.4]

 − 0.9 [− 1.3, − 0.3]

 < 0.001

 − 1.3 [− 2.0, − 0.6]

GH (ng/mL)

0.4 [0.3, 0.5]

0.5 [0.1, 0.7]

0.42

0.14 [0.08, 0.53]

Body weight on admission (kg)

106.2 [96.1, 126.0]

109.1 [97.1, 120.1]

0.82

108.8 [96.8, 121.7]

Body weight at discharge (kg)

100.6 [92.1, 115.5]

103.1 [91.7, 115.2]

0.85

101.6 [91.8, 115.3]

BMI (kg/m2)

41.5 [37.1, 49.7]

40.0 [37.1, 45.5]

0.27

40.2 [37.1, 46.5]

Systolic blood pressure (mmHg)

136.5 [125.5, 146.5]

133.6 [122.0, 146.0]

0.60

135.7 [124.5, 146.0]

Diastolic blood pressure (mmHg)

83.2 [74.0、97.0]

84.2 [77.0, 90.0]

0.80

83.9 [77.0, 91.5]

Body fat mass (kg)

57.6 [50.7, 64.8]

45.8 [42.2, 55.4]

0.043

50.3 [43.4, 58.35]

Body fat percentage (%)

53.5 [50.7, 54.5]

46.9 [41.9, 49.9]

0.0026

48.0 [43.4, 58.4]

Skeletal muscle mass index (kg/m2)

10.8 [10.5, 13.1]

11.6 [10.7, 12.2]

0.78

11.6 [10.7, 12.4]

Visceral fat area

195.3 [127.8, 266.5]

186.7 [119.9, 248.6]

0.26

188.1 [120.0, 260.0]

Subcutaneous fat area

553.8 [471.8, 621.0]

601.1 [431.6, 728.4]

0.23

593.2 [440.6, 703.2]

AST (U/L)

28.0 [19.0, 43.0]

23.0 [17.0, 36.5]

0.44

24.0 [17.5, 39.0]

ALT (U/L)

32.0 [12.0, 43.0]

32.0 [17.5, 44.0]

0.99

32.0 [16.8, 43.8]

Creatinine (mg/dL)

0.6 [0.5, 0.7]

0.7 [0.5, 0.8]

0.20

0.65 [0.53, 0.77]

eGFR (mL/min/1.73m2)

103.0 [90.5, 113.0]

92.0 [75.0, 107.0]

0.11

93.0 [80.3, 107.8]

HbA1c (%)

6.8 [6.2, 10.1]

6.7 [5.9, 9.5]

0.44

6.7 [6.0, 9.9]

Fasting blood glucose (mg/dL)

98.0 [96.0, 116.0]

105.0 [88.0, 127.0]

0.83

99.5 [88.0, 125.3]

Insulin (µIU/mL)

13.8 [8.6, 27.5]

13.9 [8.1, 18.5]

0.59

13.9 [8.5, 20.1 ]

CPR (ng/mL)

3.1 [2.3, 4.5]

3.1 [2.1, 3.8]

0.40

3.1 [2.1, 4.0]

HOMA-IR

5.7 [2.3, 6.7]

4.3 [2.1, 4.8]

0.56

4.7 [2.1, 5.0]

Natural log-transformed HS-CRPa

 − 0.16 [− 0.62, − 0.01]

 − 0.65 [− 0.95, − 0.25]

0.016

 − 0.54 [− 0.87, − 0.14]

Diabetesb

12 (70.6%)

34 (72.3%)

1.00

46 (71.9%)

Dyslipidemiab

16 (94.1%)

30 (63.8%)

0.025

46 (71.9%)

Hyperuricemiab

15 (88.2%)

19 (40.4%)

 < 0.001

34 (53.1%)

Hypertensionb

14 (82.4%)

28 (59.6%)

0.26

44 (68.8%)

  1. IGF-1 Insulin like growth factor-1, SDS standard deviation scores, GH growth hormone, BMI body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, eGFR estimated glomerular filtration rate, HbA1c hemoglobin A1c, CPR connecting-peptide immunoreactivity, HOMA-IR homeostatic model assessment for insulin resistance, HS-CRP high-sensitivity C-reactive protein.
  2. aData was transformed as necessary to maintain assumptions of normality for the purposes of the analyses. bValues are the number (%).
Back to article page